论文部分内容阅读
目的观察吉西他滨单药治疗老年晚期非小细胞肺癌的疗效和不良反应。方法对46例ⅢB～Ⅳ期老年晚期非小细胞肺癌患者采用吉西他滨1000mg/m2,第1、8天,3周重复,2个周期后评价疗效,共4～6周期。结果 44例可评价疗效,总有效率(CR+PR)为25%(11/44),中位生存期6.8个月,1a生存率为27%,不良反应以白细胞和血小板下降为常见,但均可耐受。结论吉西他滨单药治疗老年晚期非小细胞肺癌有较好疗效,可明显改善患者生存质量,延长生存时间,不良反应轻,患者易于耐受。
Objective To observe the efficacy and side effects of gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer. Methods Forty-six patients with stage ⅢB-Ⅳ advanced non-small cell lung cancer were treated with gemcitabine 1000mg / m2 for 1, 8 days and 3 weeks. The efficacy was evaluated after 2 cycles for 4 ~ 6 cycles. Results Forty-four patients were evaluated for efficacy. The overall response rate (CR + PR) was 25% (11/44). The median survival time was 6.8 months. The 1a survival rate was 27%. Adverse reactions were generally seen as leukopenia and thrombocytopenia Can be tolerated. Conclusion Gemcitabine monotherapy for the treatment of elderly patients with advanced non-small cell lung cancer has a good curative effect, which can significantly improve the quality of life of patients, prolong the survival time, adverse reactions are mild and patients are easy to tolerate.